Opioid Antagonist Market Segmentation:
Drug Type Segment Analysis
The buprenorphine segment is estimated to hold 52% share of the global opioid antagonist market by 2035. Primarily owing to its excellent clinical profile. In 2020, an estimated 1.7 million individuals reported taking buprenorphine as directed by doctor. The drug has great efficiency in managing addiction, with low potential for abuse as well as relatively mild adverse effects and its favorable formulary coverage are some of the factors that can be attributed to the high adoption of this drug.
End User Segment Analysis
The hospital segment in the opioid antagonist market is anticipated to garner significant growth during the forecast period, owing to the increasing patient pool for opium and alcohol dependency. Moreover, the critical condition of the individual addicted to drugs, and the need for specific treatment is estimated to boost the segment’s growth.
Our in-depth analysis of the global market includes the following segments:
|
Drug Type |
|
|
End User |
|
